Discover how authorized generics offer the exact same formula as brand-name drugs at lower prices. Learn the differences from traditional generics, insurance coverage, and when to switch for better value.
Read more
Discover how generic drug manufacturers use Paragraph IV certifications to challenge brand-name patents under the Hatch-Waxman Act. Learn about the 180-day exclusivity, FDA approval timelines, and the economic impact on drug prices.
Read more
Explore how hospitals balance cost, safety, and supply chain risks when selecting generic drugs. Learn about P&T committees, complex generics, and the economic pressures shaping modern formulary decisions.
Read more
Discover how insurance formularies determine generic drug coverage. Learn about P&T committee decisions, formulary tiers, and how to handle exceptions when your medication isn't covered.
Read more
A comprehensive guide to the FDA's Purple Book, explaining the critical differences between biosimilars and interchangeable biological products and how to use the database.
Read more
Explore the complexities of Chinese generic drug production, from its 80% API market dominance to critical quality gaps and the global push for supply chain diversification.
Read more
Explore how the FDA monitors foreign generic drug plants, the shift to unannounced inspections, and the impact of CGMP standards on global pharmaceutical safety.
Read more
Patent Term Restoration recovers time lost during FDA regulatory review. Learn how the Hatch-Waxman Act extends exclusivity, calculation rules, and strategic implications for pharma.
Read more